Titre :
|
Tobramycine eye drops and ocular myasthenia gravis reactivation: A case report
|
Revue :
|
Thérapie
|
Auteurs :
|
de Canecaude C ;
Gazagne C ;
Paraire M ;
Durrieu G
|
Type de document :
|
Article
|
Editeur :
|
France, 02/2020
|
Langues:
|
Anglais
|
Mots-clés :
|
adulte
;
antibiotique
;
effet indésirable
;
étude de cas
;
féminin
;
lettre
;
myasthénie oculaire
;
ptosis
|
Mots-clés:
|
aminoside;myasthenia;ptosis;tobramycin eye drops;
|
Résumé :
|
Tobramycin is an aminoside antibiotic with bactericidal properties acting on bacterial cell proteins synthesis. As eye drops, tobramycin is used as a local antibacterial drug for conjunctivitis, keratitis or corneal ulcers. For this local preparation, the sole contraindication in the summary of product characteristics (SPC) is hypersensitivity to the drug. Expected adverse drug reactions (ADRs) in the SPC of the eye drop form are mainly eye disorders and general or cutaneous manifestations of hypersensitivity. Other ‘‘serious’’ ADRs of aminoside drugs, including neurotoxicity, ototoxicity or nephrotoxicity, are only recorded for systemic but not local administration of tobramycin. We report here the occurrence of ptosis after tobramycin eye drops in a woman with a medical history of ocular myasthenia.
|
Pubmed / DOI :
|
Pubmed : 32171441 / DOI : 10.1016/j.therap.2020.02.016
|
N° Profil MNM :
|
2020032
|
En ligne :
|
http://www.ncbi.nlm.nih.gov/pubmed/32171441
|